



2026 **SCIENTIFIC
SESSIONS**

Program Information

JUNE 5–8, 2026 | NEW ORLEANS, LA

ADA2026.ORG | #ADASCISESSIONS



Welcome to the American Diabetes Association's **2026 Scientific Sessions** in New Orleans.

As the world's largest meeting on diabetes, the Scientific Sessions is both a leading educational gathering and a unique opportunity to network with colleagues from over 115 countries. We couldn't be more excited to reconnect and accelerate progress towards preventing and curing diabetes and improving the lives of all people affected by diabetes.

Welcome!

We're excited to highlight several key topics during this year's conference, including discussions focused on enhancing the quality and reach of diabetes care through improved access and cutting-edge technologies.


Browse our day-at-a-glance schedule to discover all the scientific content you won't want to miss. To help you easily navigate sessions related to health access, obesity, and technology innovation, look for the , , and  icons next to the session titles.

We look forward to exploring these critical topics and engaging in meaningful discussions.

Download the Mobile App

This guide includes maps and the day-at-a-glance schedule. **For full program details, use the online planner/mobile app.** The 2026 Scientific Sessions app is compatible with iOS and Android devices.

Program information is subject to change at any time.



Scan to view the Online Planner



TABLE OF CONTENTS

- 04 Maps
- 10 Day-at-a-Glance | Friday, June 5
- 14 Day-at-a-Glance | Saturday, June 6
- 20 Day-at-a-Glance | Sunday, June 7
- 26 Day-at-a-Glance | Monday, June 8





2026 SCIENTIFIC SESSIONS

Level 1

New Orleans Convention Center


LEVEL 1



Level 2

New Orleans Convention Center

LEVEL 2




Level 3


(above Halls D-F)

New Orleans Convention Center

LEVEL 3



THIRD FLOOR ABOVE HALLS D-F



	Acute and Chronic Complications	Behavioral Medicine, Clinical Nutrition, Education, and Exercise	Clinical Diabetes/Therapeutics	Epidemiology/Genetics
10:30 a.m.–12:30 p.m.	SPECIAL LECTURES AND ADDRESSES Welcome to the 2026 ADA Scientific Sessions: Keynote Address by Jay Bhattacharya, MD, PhD & ‘Pathway to Stop Diabetes’ Symposium Hall F (Level 1)			
12:45 p.m.–1:45 p.m.	ORAL PRESENTATIONS Top Research Abstracts: Mechanisms of Diabetic Kidney Disease Hall E-2 (Level 1)	DEBATE  Hope or Hype? Microbiome as New Frontier for Type 2 Diabetes and Obesity La Nouvelle Orleans C (Level 2)	DEBATE  Continuous Ketone Monitoring for the Masses: Risky or Rewarding? La Nouvelle Orleans B (Level 2)	
	ORAL PRESENTATIONS Management of Diabetic Retinopathy—Clinical Perspective 220 (Level 2)	ORAL PRESENTATIONS Exercise Breaks Hall E-3 (Level 1)	ORAL PRESENTATIONS Redesigning Diabetes Care: What Is the Cost? Great Hall B (Level 1)	
	ORAL PRESENTATIONS Beyond Conventional Care: Regenerative Medicine and Smart Dressings for Diabetic Foot Ulcer 217 (Level 2)		ORAL PRESENTATIONS Beyond A1C: New Ways to Measure Disease Progression in Early-Stage Type 1 Diabetes? (With ADA Presidents’ Select Abstract Presentation) 245 (Level 2)	
2:00 p.m.–3:30 p.m.	ORAL PRESENTATIONS Hypoglycemia across Contexts: Risk, Recognition, and Real-World Safety (With ADA Presidents’ Select Abstract Presentation) R05 (Level 2)	ORAL PRESENTATIONS Empowering Populations: Diabetes Self-Management Education in Practice Hall E-3 (Level 1)	ORAL PRESENTATIONS Preventing Type 1 Diabetes 245 (Level 2)	ORAL PRESENTATIONS From Plate to Pancreas: Mechanisms Linking Diet to Diabetes (With ADA Presidents’ Select Abstract Presentation) 217 (Level 2)
	ORAL PRESENTATIONS Old and New Tools to Understand Cardiovascular Risk (With Edwin Bierman Award Lecture) La Nouvelle Orleans C (Level 2)	ORAL PRESENTATIONS What Works? Outcomes of Behavioral Intervention Trials in Type 1, Type 2, and Gestational Diabetes Great Hall A (Level 1)	ORAL PRESENTATIONS  Session #1: What’s New with Insulin Delivery Systems? (With ADA Presidents’ Select Abstract Presentation) La Nouvelle Orleans B (Level 2)	ORAL PRESENTATIONS Multiomic Approaches and Resources for Providing Insights into Diabetes Pathophysiology R07 (Level 2)
			ORAL PRESENTATIONS  Adapting Diabetes Care for All (With Felicia Hill-Briggs Trailblazer in Health Equity Award Lecture) Great Hall B (Level 1)	
			ORAL PRESENTATIONS Neonatal and Childhood Outcomes of Dysglycemia in Pregnancy (With Norbert Freinkel Award Lecture) Hall E-2 (Level 1)	

Immunology/Beta-Cell Replacement	Insulin Action/Molecular Metabolism	Islet Biology/Insulin Secretion	Obesity/Integrated Physiology	Professional Development
SPECIAL LECTURES AND ADDRESSES Welcome to the 2026 ADA Scientific Sessions: Keynote Address by Jay Bhattacharya, MD, PhD & ‘Pathway to Stop Diabetes’ Symposium Hall F (Level 1)				
ORAL PRESENTATIONS Immune Heterogeneity and Endotypes in Type 1 Diabetes: Insights from Human Studies and Humanized Models 343 (Level 3)	PANEL DISCUSSION Insulin Resistance: A Cause or Consequence of Metabolic Dysfunction? 356 (Level 3)	ORAL PRESENTATIONS Human Islet Cell Identity and Organization 355 (Level 3)	ORAL PRESENTATIONS  Human Studies in Obesity Treatment: Emerging Therapeutic Options and Strategies for Decision-Making Great Hall A (Level 1)	
	ORAL PRESENTATIONS Molecular Transducers of Insulin Action and Insulin Resistance 356 (Level 3)	ORAL PRESENTATIONS Decoding Islet Electrophysiology: Channels, Pumps, and Metabolic Coupling 355 (Level 3)	ORAL PRESENTATIONS  Preserving Lean Mass with GLP-1R Therapy: Preclinical Obesity Studies 343 (Level 3)	
			ORAL PRESENTATIONS Hypothalamic Circuits and Neuroendocrine Control of Glucose Homeostasis 220 (Level 2)	

	Acute and Chronic Complications	Behavioral Medicine, Clinical Nutrition, Education, and Exercise	Clinical Diabetes/ Therapeutics	Epidemiology/ Genetics
3:45 p.m.–5:15 p.m.	SYMPOSIUM Personalizing Diabetes Care: Tailoring the Intervention to the Cardiovascular Risk La Nouvelle Orleans C (Level 2)	PANEL DISCUSSION Inpatient Glucose Management: Clinical and Quality Perspectives in the Age of eCQMs 220 (Level 2) SYMPOSIUM  ADA ERP Symposium: Standardizing Diabetes Education on a Global Level Hall E-3 (Level 1)  SYMPOSIUM Expanding Health Access: Translating Science into Practice Through Community-Engaged Approaches Great Hall B (Level 1)  SYMPOSIUM Bridging the Gap: Real-Time Diabetes Technology, Organizational Readiness, and Policy Solutions to Advance Care 217 (Level 2)  SYMPOSIUM Are We Ready to Meet the Needs of Older Adults with Type 1 Diabetes? 245 (Level 2)  SYMPOSIUM Amylin as a Novel Diabetes and Obesity Therapy Great Hall A (Level 1)	PANEL DISCUSSION Make New Friends, but Keep the Old? Updates on Insulin Therapy in Pregnancy Hall E-2 (Level 1)  SYMPOSIUM Expanding Health Access: Translating Science into Practice Through Community-Engaged Approaches Great Hall B (Level 1)  SYMPOSIUM Bridging the Gap: Real-Time Diabetes Technology, Organizational Readiness, and Policy Solutions to Advance Care 217 (Level 2)  SYMPOSIUM Are We Ready to Meet the Needs of Older Adults with Type 1 Diabetes? 245 (Level 2)  SYMPOSIUM Amylin as a Novel Diabetes and Obesity Therapy Great Hall A (Level 1)	PANEL DISCUSSION Mapping Diabetes: Epidemiology in a Changing U.S. Demographic Landscape R05 (Level 2)
5:30 p.m.–6:30 p.m.	DEBATE Level 1 Hypoglycemia: Does It Really Matter? La Nouvelle Orleans C (Level 2) ORAL PRESENTATIONS Top Clinical Abstracts: Kidney Complications in Diabetes (With ADA Presidents’ Select Abstract Presentation) Hall E-2 (Level 1) ORAL PRESENTATIONS Frontiers in Diabetic Nerve Health: Biomarkers, Risk, Diagnosis, and Treatment 217 (Level 2)	ORAL PRESENTATIONS New Ways to Learn, Support, and Grow in Diabetes Care (With ADA Presidents’ Select Abstract Presentation) Hall E-3 (Level 1) ORAL PRESENTATIONS Exercise Training, Fatigue and Motivation R05 (Level 2) ORAL PRESENTATIONS Diverse Nutritional Approaches to Modify Metabolism in Type 2 Diabetes 245 (Level 2)	ORAL PRESENTATIONS New Tools, Same Focus: Targeting Microvascular Disease in Type 2 Diabetes Great Hall B (Level 1) SYMPOSIUM Dual Agonism in Type 1 Diabetes: Unveiling Efficacy and Safety of Adjunct Therapy with CT-868 (GLP-1/GIP RA) in Adults with Type 1 Diabetes—Phase 1 and 2 Results Great Hall A (Level 1)	
6:30 p.m.–8:30 p.m.	NETWORKING RECEPTION American Diabetes Association Networking Reception Exhibit Hall (Halls B1-C2; Level 1)			

Immunology/ Beta-Cell Replacement	Insulin Action/ Molecular Metabolism	Islet Biology/ Insulin Secretion	Obesity/Integrated Physiology	Professional Development
SYMPOSIUM Joint ADA/IPITA Symposium: Engineering Transplantation Sites to Improve Beta-Cell Survival and Function 355 (Level 3)	SYMPOSIUM Exercise Signals and the Interorgan Metabolic Dialogue 356 (Level 3)		 SYMPOSIUM Obesity Year in Review: Major Advances and Discoveries La Nouvelle Orleans B (Level 2)  SYMPOSIUM Novel Metabolic Drivers Underlying the Development of Obesity 343 (Level 3)	
ORAL PRESENTATIONS Beyond Engraftment: Functional Readouts, Counterregulation, and the Lived Experience of Islet Transplantation 355 (Level 3)	ORAL PRESENTATIONS Controlling the Metabolic Phenotype of Fat: New Insights into Local and Distal Signals 356 (Level 3)		 DEBATE BMI on Trial: Should It Still Define Obesity La Nouvelle Orleans B (Level 2) ORAL PRESENTATIONS Pathways Regulating Glycemia: Insulin Sensitization, β-Cell Reserve, and Glucose Sensing 343 (Level 3)	
NETWORKING RECEPTION American Diabetes Association Networking Reception Exhibit Hall (Halls B1-C2; Level 1)				

	Acute and Chronic Complications	Behavioral Medicine, Clinical Nutrition, Education, and Exercise	Clinical Diabetes/ Therapeutics	Epidemiology/ Genetics
8:00 a.m.–9:30 a.m.	PANEL DISCUSSION Breaking the Pain Chain: Practical Strategies for Diabetic Neuropathy from Diagnosis to Treatment 217 (Level 2) SYMPOSIUM Rethinking RAAS: Novel Strategies to Target a Classic Pathway in Diabetic Kidney Disease Hall E-2 (Level 1) SYMPOSIUM How Do Lipoproteins Control Blood Glucose Levels/Insulin Secretion: Insulin Sensitivity Hall E-3 (Level 1)	PANEL DISCUSSION Exercise in the Age of Digital Health 220 (Level 2) SYMPOSIUM ADA DSMES/Nutrition Symposium: Disordered Eating in Diabetes and Obesity Great Hall B (Level 1)	SYMPOSIUM The ADA's <i>Standards of Care in Diabetes</i>: 2026 Updates La Nouvelle Orleans B (Level 2) SYMPOSIUM AI Integration into Diabetes Technology La Nouvelle Orleans C (Level 2) SYMPOSIUM The VESPER-1, -2 and -3 Trials of MET-097 (PF-08653944), an Ultra-Long-Acting GLP-1 Receptor Agonist for Weight Management Great Hall A (Level 1)	SYMPOSIUM Using Genetics to Elucidate Atypical Diabetes R05 (Level 2)
9:45 a.m.–11:15 a.m.	SPECIAL LECTURES AND ADDRESSES ADA Remarks; President, Health Care & Education Address; and Distinguished International Service in the Cause of Diabetes Award Lecture Hall F (Level 1)			
11:30 a.m.–12:30 p.m.		EPOSTER THEATER (*) Educating Patients with Diabetes beyond the Clinic Walls ePoster Theater A (Halls B1-C) PROFESSIONAL INTEREST GROUP Discussion on Behavioral Medicine and Psychology: Beyond Boundaries—Expanding Your Behavioral Medicine Research Portfolio 245 (Level 2) PROFESSIONAL INTEREST GROUP Discussion on Exercise Physiology: MoTrPAC—What Does It Tell Us About Diabetes and Physical Activity? 355 (Level 3) PROFESSIONAL INTEREST GROUP Discussion on Women's Interprofessional Network of the ADA (WIN ADA): The Adaptive Edge—How to Lead Through Change Panel Discussion Hall E-3 (Level 1)	PROFESSIONAL INTEREST GROUP Discussion on Diabetes in Primary Care: Optimizing Use, Safety, and Tolerability of Diabetes Medications La Nouvelle Orleans C (Level 2) PROFESSIONAL INTEREST GROUP Discussion on Health Care Delivery and Quality Improvement: From Best Practices to Value—Scaling Diabetes Expertise Through Innovation 356 (Level 3) PROFESSIONAL INTEREST GROUP Discussion on Pregnancy and Reproductive Health: Adverse Outcomes in GDM-Hyperglycemia or Obesity? Hall E-2 (Level 1) PROFESSIONAL INTEREST GROUP Discussion on Clinical Centers and Programs: Diabetes Management in Older Adults—Challenges and Opportunities 343 (Level 3)	

Immunology/ Beta-Cell Replacement	Insulin Action/ Molecular Metabolism	Islet Biology/ Insulin Secretion	Obesity/Integrated Physiology	Professional Development
SYMPOSIUM Harnessing Big Data to Decode Immune Mechanisms in Type 1 Diabetes 343 (Level 3)		SYMPOSIUM Sexual Dimorphism in Islet Responses in the Setting of Diabetes and Obesity 356 (Level 3)	SYMPOSIUM The Pancreas Revealed: New Ways to Measure Form and Function 355 (Level 3) SYMPOSIUM Is Obesity Accelerated Aging? A Physiologic Perspective 245 (Level 2)	
SPECIAL LECTURES AND ADDRESSES ADA Remarks; President, Health Care & Education Address; and Distinguished International Service in the Cause of Diabetes Award Lecture Hall F (Level 1)				
		EPOSTER THEATER (*) Islet Development, Adaptation and Failure ePoster Theater B (Halls B1-C)	PROFESSIONAL INTEREST GROUP Discussion on Obesity: Reclaiming the Full Spectrum of Obesity Care La Nouvelle Orleans B (Level 2)	

	Acute and Chronic Complications	Behavioral Medicine, Clinical Nutrition, Education, and Exercise	Clinical Diabetes/ Therapeutics	Epidemiology/ Genetics
12:30 p.m.–1:30 p.m.	General Poster Session POSTER HALL (HALLS D-E) Session Break (Take this opportunity to visit the Exhibit and Poster Halls)			
			EPOSTER THEATER (*) Reimaging Clinical Type 1 Diabetes Care ePoster Theater B (Halls B1-C)	
1:30 p.m.–3:00 p.m.	ORAL PRESENTATIONS Biology and Assessment of Cardiovascular Risk R07 (Level 2)	ORAL PRESENTATIONS Contemporary and Emerging Diabetes Technologies and Therapies: Psychosocial and Behavioral Considerations (With Richard R. Rubin Award Lecture) La Nouvelle Orleans B (Level 2)	EPOSTER THEATER (*) Advances in Clinical Therapeutics for Type 1 and Type 2 Diabetes ePoster Theater A (Halls B1-C) ORAL PRESENTATIONS Preventing Type 2 Diabetes: Recent Advances Great Hall B (Level 1) ORAL PRESENTATIONS Session #1: What's New with CGM Systems? La Nouvelle Orleans C (Level 2) ORAL PRESENTATIONS To Pay or Not to Pay R05 (Level 2) ORAL PRESENTATIONS Maternal Metabolic Health In and Beyond Pregnancy Hall E-2 (Level 1) SYMPOSIUM Beyond Insulin: Adjunctive Therapies for Pediatric Type 1 Diabetes 245 (Level 2) SYMPOSIUM Unlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Retatrutide: A Triple Agonist, Activating the GIP, GLP-1 and Glucagon Receptors (TRANSCEND-T2D-1 and TRIUMPH-1 Results) Great Hall A (Level 1)	EPOSTER THEATER (*) Pills, Pumps, and Protection: Diabetes Therapeutics ePoster Theater B (Halls B1-C)

Immunology/ Beta-Cell Replacement	Insulin Action/ Molecular Metabolism	Islet Biology/ Insulin Secretion	Obesity/Integrated Physiology	Professional Development
General Poster Session POSTER HALL (HALLS D-E) Session Break (Take this opportunity to visit the Exhibit and Poster Halls)				
			EPOSTER THEATER (*) From Mouse to Human: Translational Insights into Metabolism ePoster Theater A (Halls B1-C)	
ORAL PRESENTATIONS Novel Insights into Basics Mechanisms and Therapeutic Interventions in Type 1 Diabetes Hall E-3 (Level 1)	ORAL PRESENTATIONS Metabolic Programming during Development and Aging 217 (Level 2)	ORAL PRESENTATIONS Molecular and Therapeutic Strategies for Diabetes 356 (Level 3)	ORAL PRESENTATIONS Translational Studies of Mechanisms Underlying Weight Gain and Long-Term Weight Loss in Obesity 343 (Level 3) ORAL PRESENTATIONS Metabolic Flexibility in Humans: Integrating Organ Fuel and Metabolite Handling (With ADA Presidents' Select Abstract Presentation) 355 (Level 3)	

	Acute and Chronic Complications	Behavioral Medicine, Clinical Nutrition, Education, and Exercise	Clinical Diabetes/Therapeutics	Epidemiology/Genetics
3:15 p.m.–4:15 p.m.	DEBATE How to Best Combine Therapies for Patients with Diabetic Kidney Disease? La Nouvelle Orleans B (Level 2)	ASK THE EXPERT Vapes and Vodka: What Every Diabetes Professional Should Know about Addressing Adolescent and Young Adult Substance Use Hall E-2 (Level 1)	DEBATE GLP-1 Receptor Agonists: The Optimal First-Line Therapy for Early Pediatric Type 2 Diabetes? La Nouvelle Orleans C (Level 2)	DEBATE Precision Medicine in Diabetes: Is It Time to Bring Genetics to the Clinic? 343 (Level 3)
	SYMPOSIUM The Molecular Nexus: Inflammation, ECM, and Angiogenesis as Therapeutic Targets for Diabetic Foot Wounds 220 (Level 2)		ORAL PRESENTATIONS Newer Concepts in Management of Diabetes and Hypertriglyceridemia Hall E-3 (Level 1)	ORAL PRESENTATIONS Type 1 Diabetes: Trends, Complications, and Survival 245 (Level 2)
	SYMPOSIUM Are GLP-1 Receptor Agonists Safe for the Eyes? 217 (Level 2)		SYMPOSIUM Quality Improvement Initiatives at Scale: What Have We Learned? R07 (Level 2)	
			SYMPOSIUM ADA Statement on Diabetes Technology in Primary Care R05 (Level 2)	
			SYMPOSIUM ADA EASD Consensus Statement on Management of Type 2 Diabetes: Management of Hyperglycemia in Type 2 Diabetes Great Hall A (Level 1)	
4:30 p.m.–6:00 p.m.	(*) Innovation Challenge Hall F (Level 1)			
	SYMPOSIUM The Diabetic Foot Consortium: An NIDDK Initiative to Transform Care of the Diabetic Foot Ulcer 220 (Level 2)	SYMPOSIUM Consensus or Controversy? Hot Topics in Nutrition 2026 Hall E-3 (Level 1)	PANEL DISCUSSION Overcoming Technology Limitations La Nouvelle Orleans C (Level 2)	SYMPOSIUM ADA Diabetes Journal Symposium: Non-Classical Complications of Diabetes—Epidemiology, Mechanism, Treatment La Nouvelle Orleans B (Level 2)
			SYMPOSIUM Joint ADA/AACC Symposium: Expecting the Best—Laboratory Issues in the Diagnosis and Management of Diabetes in Pregnancy Hall E-2 (Level 1)	SYMPOSIUM Advancing Diabetes Epidemiology with Real-World Data and AI 217 (Level 2)
			SYMPOSIUM Beta-Cell Replacement in Pediatric Type 1 Diabetes: Promise and Perspective 355 (Level 3)	

Immunology/ Beta-Cell Replacement	Insulin Action/ Molecular Metabolism	Islet Biology/ Insulin Secretion	Obesity/Integrated Physiology	Professional Development
PANEL DISCUSSION Bridging the Gap: Advancing Stem Cell-Derived Beta- Cell Therapy toward Widespread Clinical Use 355 (Level 3)		ASK THE EXPERT It's Not Up for Debate: Paracrine Signaling Is Critical in Shaping Insulin Secretion 356 (Level 3)	PANEL DISCUSSION Perspectives from ADA Banting Medalists on Obesity Pathogenesis: Current State and Future Directions Great Hall B (Level 1)	
 (*) Innovation Challenge Hall F (Level 1)				
SYMPOSIUM Immune System Engineering for Type 1 Diabetes: From Mechanisms to Therapies 245 (Level 2)		PANEL DISCUSSION Why Would We Do Away with the Mouse? Animal and Human Research Are Complementary! 356 (Level 3)	SYMPOSIUM Updated Understanding of Reward Processing in Obesity in the Era of Incretin Agonists 343 (Level 3)	

	Acute and Chronic Complications	Behavioral Medicine, Clinical Nutrition, Education, and Exercise	Clinical Diabetes/ Therapeutics	Epidemiology/ Genetics
8:00 a.m.–9:30 a.m.	ASK THE EXPERT Goals in Common: Recent Updates to the Guidelines—Blood Pressure, Lipids, and Heart Failure 355 (Level 3)	PANEL DISCUSSION From Evidence to the Plate: What the New Nutrition Guidelines Mean for Diabetes Care Hall E-3 (Level 1) PANEL DISCUSSION Physiological Effects of Exercise R07 (Level 2) SYMPOSIUM Harnessing Technology to Tackle Diabetes Distress: Innovations across Diabetes Types and Life Stages R05 (Level 2)	ORAL PRESENTATIONS Innovative Approaches to Weight Management 217 (Level 2) ORAL PRESENTATIONS Metabolic and Glycemic Profiles in Pregnancies Affected by Diabetes Hall E-2 (Level 1) PANEL DISCUSSION GLP-1RA Across the Lifespan: Who, When, and at What Cost? 220 (Level 2) SYMPOSIUM ADA Diabetes, Obesity, and Cardiometabolic CARE (DOCM CARE) Journal Symposium: The Cost of Obesity and its Treatment Great Hall B (Level 1) SYMPOSIUM Evolving Therapies for MASH 245 (Level 2) SYMPOSIUM The AIDING Trial: Automated Insulin Delivery in the Hospital—Results and Implications for Inpatient Diabetes Care Great Hall A (Level 1)	SYMPOSIUM Rising Minds: AI Innovations in Diabetes—NIDDK Early-Career Investigator Symposium La Nouvelle Orleans C (Level 2) SYMPOSIUM Pharmacogenomic Responses in Diabetes: From Mice to Medications 343 (Level 3)
9:45 a.m.–11:15 a.m.	SPECIAL LECTURES AND ADDRESSES President, Medicine & Science Address and Banting Medal for Scientific Achievement Award Lecture Hall F (Level 1)			
11:30 a.m.–12:30 p.m.	PROFESSIONAL INTEREST GROUP Discussion on Diabetes and Cardiovascular Disease: Implementing a Multi-Disciplinary Approach in Patients with Diabetes and Cardiovascular Disease La Nouvelle Orleans C (Level 2) PROFESSIONAL INTEREST GROUP Discussion on Eye Health: Use of AI in Diabetic Retinopathy Screening 343 (Level 3)	EPOSTER THEATER (*) The Social Context of Life with Diabetes ePoster Theater A (Halls B1-C) PROFESSIONAL INTEREST GROUP Discussion on Diabetes Self-Management Education and Support (DSMES): Advancing Prandial Insulin Education Within DSMES—Findings From a Toolkit Pilot Hall E-2 (Level 1)	PROFESSIONAL INTEREST GROUP Discussion on Diabetes in Youth: From Uncertainty to Action—Mobilizing Advocacy for Type 1 and Type 2 Diabetes Amid Shifting Landscapes La Nouvelle Orleans B (Level 2)	PROFESSIONAL INTEREST GROUP Discussion on Public Health and Epidemiology: Leveraging Technology to Disseminate Diabetes Care to Under-Resourced Populations Hall E-3 (Level 1)

Immunology/ Beta-Cell Replacement	Insulin Action/ Molecular Metabolism	Islet Biology/ Insulin Secretion	Obesity/Integrated Physiology	Professional Development
SYMPOSIUM Emerging Insights from Type 1 Diabetes Immunotherapy Clinical Trials La Nouvelle Orleans B (Level 2)			SYMPOSIUM Central Command (or Can We?): Insights into whether Modulating the Nervous System Can Improve Metabolic Health 356 (Level 3)	
SPECIAL LECTURES AND ADDRESSES President, Medicine & Science Address and Banting Medal for Scientific Achievement Award Lecture Hall F (Level 1)				
		PROFESSIONAL INTEREST GROUP Discussion on Islet Biology, Development, and Function: Small, but Mighty—Extra Islet Beta-Cells are Preserved or Lost in Type 1 Diabetes? 355 (Level 3)	EPOSTER THEATER (*) Obesity Treatment: Comparisons, Outcomes, and Effects ePoster Theater B (Halls B1-C)	PROFESSIONAL DEVELOPMENT Engaging Science: Talks that Matter 245 (Level 2)

	Acute and Chronic Complications	Behavioral Medicine, Clinical Nutrition, Education, and Exercise	Clinical Diabetes/ Therapeutics	Epidemiology/ Genetics
12:30 p.m.–1:30 p.m.	General Poster Session POSTER HALL (HALLS D-E) Session Break (Take this opportunity to visit the Exhibit and Poster Halls)			
			EPOSTER THEATER (*) What's New in Diabetes Technologies? ePoster Theater A (Halls B1-C) 	EPOSTER THEATER (*) Diabetes Risk and Prediction: One Size Does Not Fit All ePoster Theater B (Halls B1-C)
1:30 p.m.–3:00 p.m.	 SYMPOSIUM The New Frontier of Hypoglycemia Prevention: Pathophysiology, Therapies, Technology, and Care R07 (Level 2)	 PANEL DISCUSSION Beyond Screening: Supporting Mental and Behavioral Health among Youth and Families at Risk for Stage 3 Type 1 Diabetes R05 (Level 2)	 ASK THE EXPERT AI and Innovation for Clinical Health Care Delivery in DM Hall E-3 (Level 1)  SYMPOSIUM Standards of Care in Overweight and Obesity: 2026 Updates Great Hall B (Level 1)  SYMPOSIUM ADA Diabetes Care Symposium: The Oscillation of Diabetes and the Environment 245 (Level 2) SYMPOSIUM Diabetes Year in Review: Major Advances and Discoveries La Nouvelle Orleans C (Level 2)  SYMPOSIUM The Benefits of Glucagon/ GLP-1 Receptor Dual Agonism: Insights from the SYNCHRONIZE™ Phase 3 Studies of Survodutide Great Hall A (Level 1)	 PANEL DISCUSSION Addressing the Growing Diabetes Epidemic: Global Perspectives Hall E-2 (Level 1)

Immunology/ Beta-Cell Replacement	Insulin Action/ Molecular Metabolism	Islet Biology/ Insulin Secretion	Obesity/Integrated Physiology	Professional Development
General Poster Session POSTER HALL (HALLS D-E) Session Break (Take this opportunity to visit the Exhibit and Poster Halls)				
SYMPOSIUM Immune Modulatory Strategies for Next-Generation Cell Therapies 343 (Level 3)	 DEBATE Muscle Loss in GLP-1 Receptor Agonist–Induced Weight Loss: A Real Concern or Much Ado about Nothing? La Nouvelle Orleans B (Level 2)	SYMPOSIUM Expanding the Beta-Cell Pool: What's New with Proliferation, Neogenesis, and Transdifferentiation 355 (Level 3)	SYMPOSIUM Signals In, Signals Out: The Human Brain–Body Metabolic Circuit 356 (Level 3)	

	Acute and Chronic Complications	Behavioral Medicine, Clinical Nutrition, Education, and Exercise	Clinical Diabetes/Therapeutics	Epidemiology/Genetics
3:15 p.m.–4:00 p.m.	DEBATE Everyone Should Screen for PAD Hall E-2 (Level 1) ORAL PRESENTATIONS Counterregulatory Responses to Hypoglycemia: New Tools and Therapeutic Levers R07 (Level 2) ORAL PRESENTATIONS In Search of Novel Therapeutic Targets in Diabetic Retinopathy 217 (Level 2) ORAL PRESENTATIONS Short Talks from Abstracts, Clinical Updates on PCSK9 Inhibition and Triglyceride-Related CVD 220 (Level 2)	ORAL PRESENTATIONS Food Is Medicine Outcomes for Diabetes Management: Comparative Effectiveness across Populations Hall E-3 (Level 1)	ORAL PRESENTATIONS Novel Approaches to Glucose Control (With ADA Presidents' Select Abstract Presentation) Great Hall B (Level 1) ORAL PRESENTATIONS Session #2: What's New with Insulin Delivery Systems? La Nouvelle Orleans B (Level 2) SYMPOSIUM Update of the ADA-EASD Consensus Report on the Management of Type 1 Diabetes in Adults Great Hall A (Level 1)	ORAL PRESENTATIONS Diabetes Prediction with Polygenic and Metabolic Risk Scores R05 (Level 2) SPECIAL LECTURES AND ADDRESSES Kelly West Award for Outstanding Achievement in Epidemiology Lecture 245 (Level 2)
4:30 p.m.–6:00 p.m.	SYMPOSIUM Unexplored Pathways of Residual Risk in Diabetic Kidney Disease to Find Novel Cures R07 (Level 2)	ASK THE EXPERT Diabetes Care and Education for Everyone, Wherever They Are Hall E-3 (Level 1)	ASK THE EXPERT Getting Along with Your Algorithm Hall E-2 (Level 1) PANEL DISCUSSION Early Pregnancy Diabetes Screening Reexamined: GO MOMs or Hold Tight? 217 (Level 2) SYMPOSIUM Where Heart, Kidney, and Metabolism Collide: Innovations in the Holistic Approach to Care Great Hall B (Level 1) SYMPOSIUM REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care with CagriSema Great Hall A (Level 1) SYMPOSIUM 2026 ADA State of Type 1 Diabetes La Nouvelle Orleans C (Level 2)	PANEL DISCUSSION Diabetes on the Radar: From Smart Data to Smarter Policy R05 (Level 2)

Immunology/Beta-Cell Replacement	Insulin Action/Molecular Metabolism	Islet Biology/Insulin Secretion	Obesity/Integrated Physiology	Professional Development
	ORAL PRESENTATIONS Advances in Metabolic Therapeutics: A Focus on Insulin Sensitivity and Adipose Function 343 (Level 3)	ORAL PRESENTATIONS Determinants of β-Cell Immunogenicity and Survival in Type 1 Diabetes 355 (Level 3)	DEBATE The Glucagon Agonism Paradox: Friend or Foe in the Fight against Hyperglycemia? La Nouvelle Orleans C (Level 2) ORAL PRESENTATIONS Perturb & Observe: What Pharmacologic Challenges Reveal About Human Metabolism 356 (Level 3)	
SYMPOSIUM Lessons from Islet Biology for Next-Generation Therapies 355 (Level 3)	SYMPOSIUM Metabolic Control in Obesity and Diabetes via Interocception 356 (Level 3)	SYMPOSIUM 2026 Diabetes/Diabetes Care/Diabetologia Symposium: Where Are the Beta Cell Lesions Underlying Type 2 Diabetes? La Nouvelle Orleans B (Level 2)	PANEL DISCUSSION Global Perspectives on Obesity Care 245 (Level 2)	

	Acute and Chronic Complications	Behavioral Medicine, Clinical Nutrition, Education, and Exercise	Clinical Diabetes/ Therapeutics	Epidemiology/ Genetics
8:00 a.m.–9:30 a.m.	SYMPOSIUM Molecular Architecture of Diabetic Retinopathy: Genes and Epigenomics R05 (Level 2)	SYMPOSIUM From Innovation to Integration: Redefining the Scale and Sustainability of Diabetes Prevention Through a National Framework 245 (Level 2) SYMPOSIUM Lady Parts (of Life with Diabetes): Behavioral and Psychosocial Care for Women Hall E-2 (Level 1)	PANEL DISCUSSION Diabetes Technology Use across Life Situations Hall E-3 (Level 1) SYMPOSIUM Joint ADA/ISPAD Symposium: A Global Perspective on Pediatric Type 1 Diabetes Screening La Nouvelle Orleans B (Level 2) SYMPOSIUM Maternal Metabolic Imprinting: New Insights on Developmental Origins of Diabetes and Obesity 217 (Level 2) SYMPOSIUM GLP-1 Receptor Agonists: What's New in 2026? Great Hall A (Level 1) SYMPOSIUM How Do We Close Gaps in Access to Obesity Care? Great Hall B (Level 1) SYMPOSIUM The ADA and Centers for Diabetes Translation Research Symposium: Driving Innovation in Diabetes Translation 220 (Level 2)	SYMPOSIUM Lancet Journal Symposium: Cardiometabolic Multiple Long-Term Conditions (Multimorbidity)—Epidemiology, Mechanisms, Models, and Management La Nouvelle Orleans C (Level 2)
9:45 a.m.–11:15 a.m.	 SPECIAL LECTURES AND ADDRESSES National Scientific & Health Care Achievement Awards Presentation, Outstanding Scientific Achievement Award Lecture and Outstanding Educator in Diabetes Award Lecture Hall F (Level 1)			

Immunology/ Beta-Cell Replacement	Insulin Action/ Molecular Metabolism	Islet Biology/ Insulin Secretion	Obesity/Integrated Physiology	Professional Development
	SYMPOSIUM Organellar Metabolite Carriers: A New Frontier in Metabolic Research 356 (Level 3)	SYMPOSIUM The Pancreatic Ecosystem: How Exocrine Tissue Orchestrates Islet Biology 355 (Level 3)	SYMPOSIUM Mitochondrial Energetics in Obesity 343 (Level 3)	
 SPECIAL LECTURES AND ADDRESSES National Scientific & Health Care Achievement Awards Presentation, Outstanding Scientific Achievement Award Lecture and Outstanding Educator in Diabetes Award Lecture Hall F (Level 1)				

	Acute and Chronic Complications	Behavioral Medicine, Clinical Nutrition, Education, and Exercise	Clinical Diabetes/Therapeutics	Epidemiology/Genetics
11:30 a.m.–12:30 p.m.	PROFESSIONAL INTEREST GROUP Discussion on Foot Care: Revolutionizing Diabetic Limb Salvage—Vascular Innovation, Bone Health, and Regenerative Strategies in Lower Extremities Hall E-3 (Level 1)	PROFESSIONAL INTEREST GROUP Discussion on Nutritional Science and Metabolism: Diabetes and Nutrition Across the Perinatal Continuum—From Preconception to Postpartum La Nouvelle Orleans C (Level 2)	EPOSTER THEATER (*) Healthcare Delivery: Expanding Beyond the Individual ePoster Theater A (Halls B1-C) EPOSTER THEATER (*) Diabetes in Pregnancy: Mechanisms, Management, and Metabolic Imprinting ePoster Theater B (Halls B1-C) PROFESSIONAL INTEREST GROUP   Discussion on Diabetes Technology: Addressing Unmet Needs in Diabetes Technology—Expanding Access to Devices La Nouvelle Orleans B (Level 2)	
12:30 p.m.–1:30 p.m.	General Poster Session POSTER HALL (HALLS D-E) Session Break (Take this opportunity to visit the Exhibit and Poster Halls)			
			EPOSTER THEATER (*) Clinical Therapeutics ePoster Theater B (Halls B1-C)	

Immunology/Beta-Cell Replacement	Insulin Action/Molecular Metabolism	Islet Biology/Insulin Secretion	Obesity/Integrated Physiology	Professional Development
PROFESSIONAL INTEREST GROUP Discussion on Immunology and Beta-Cell Replacement: Immune Tolerance in Type 1 Diabetes—Harnessing the Power of Regulatory T Cells Hall E-2 (Level 1)				PROFESSIONAL DEVELOPMENT Strengthening Community Engagement Principles in Your Research: Best Practices and Lessons Learned from the National Center for Engagement in Diabetes Research 245 (Level 2)
General Poster Session POSTER HALL (HALLS D-E) Session Break (Take this opportunity to visit the Exhibit and Poster Halls)				
			EPOSTER THEATER (*) Transformational Translational Research in Diabetes ePoster Theater A (Halls B1-C)	

	Acute and Chronic Complications	Behavioral Medicine, Clinical Nutrition, Education, and Exercise	Clinical Diabetes/ Therapeutics	Epidemiology/ Genetics
1:30 p.m.–3:00 p.m.	ORAL PRESENTATIONS Novel and Established Interventions to Improve Cardiovascular Outcomes La Nouvelle Orleans C (Level 2)	ORAL PRESENTATIONS New Directions and Novel Approaches—Early Stage and Pilot/Feasibility Research on Innovations in Diabetes Behavioral Interventions 245 (Level 2)	ORAL PRESENTATIONS Preventing Diabetes-Related Complications Hall E-3 (Level 1) ORAL PRESENTATIONS Session #2: What's New with CGM Systems? Hall E-2 (Level 1) ORAL PRESENTATIONS The Team, The Team, The Team! What Works in Health Care Team Delivery 217 (Level 2) SYMPOSIUM Joint ADA/International Diabetes Federation (IDF) Symposium: What Is Malnutrition-Related Diabetes? La Nouvelle Orleans B (Level 2) SYMPOSIUM Managing Diabetes across the Cancer Continuum: From Treatment to Survivorship Great Hall B (Level 1) SYMPOSIUM From Pen to Pill: Achieving a Paradigm Shift in Type 2 Diabetes—The Orforglipron “ACHIEVE” Clinical Trial Program Great Hall A (Level 1)	ORAL PRESENTATIONS Beyond Sugar: Synapses and Senescence 220 (Level 2)

Immunology/ Beta-Cell Replacement	Insulin Action/ Molecular Metabolism	Islet Biology/ Insulin Secretion	Obesity/Integrated Physiology	Professional Development
ORAL PRESENTATIONS Reprogram, Replicate, Replace: Experimental Approaches to Durable B-Cell Restoration 355 (Level 3)			ORAL PRESENTATIONS GLP-1 and What Else? Preclinical Obesity Studies 343 (Level 3) ORAL PRESENTATIONS Glucagon Takes the Stage: Regulation, Secretion, and When the Pancreas Goes Off-Script R07 (Level 2) ORAL PRESENTATIONS Hepatic Signaling Networks Driving Metabolic Dysfunction and MASLD R05 (Level 2) SYMPOSIUM Neuronal Circuits and Plasticity Linking Energy Balance and Feeding in Obesity 356 (Level 3)	

	Acute and Chronic Complications	Behavioral Medicine, Clinical Nutrition, Education, and Exercise	Clinical Diabetes/ Therapeutics	Epidemiology/ Genetics
3:15 p.m.–4:15 p.m.	SYMPOSIUM Mechanisms and Treatments for Autonomic Dysfunction: Current Evidence and Emerging Directions 220 (Level 2)	ORAL PRESENTATIONS The Transformative Power of Continuous Glucose Monitoring Hall E-3 (Level 1)	DEBATE Immediate AI Integration into Health Care Delivery: Considering Costs, Quality, and Clinician Burnout La Nouvelle Orleans C (Level 2)	SYMPOSIUM Global Advances in Research to Address Heterogeneity of Diabetes (NIDDK) 245 (Level 2)
	SYMPOSIUM How Does MASLD Impact Lipoprotein Biology and Cardiovascular Risk with Obesity and Diabetes? R05 (Level 2)		ORAL PRESENTATIONS Session #3: What's New with CGM Systems? Hall E-2 (Level 1)	SYMPOSIUM Old Problems, Bold Solutions: Transforming Diabetes Screening with Innovative Solutions 343 (Level 3)
			SYMPOSIUM Pregnancy Pregame: Hot Topics in Preconception Management of Diabetes and Obesity 217 (Level 2)	
			SYMPOSIUM Anticipated and Unanticipated Side Effects of SGLT2 Inhibitors in Diabetes Great Hall B (Level 1)	
			SYMPOSIUM AZD5004, A Novel Oral Small Molecule GLP-1 Receptor Agonist: Overweight/Obesity (VISTA) and Type 2 Diabetes (SOLSTICE) Phase 2 Trial Results Great Hall A (Level 1)	

Immunology/ Beta-Cell Replacement	Insulin Action/ Molecular Metabolism	Islet Biology/ Insulin Secretion	Obesity/Integrated Physiology	Professional Development
PANEL DISCUSSION B Cells in Type 1 Diabetes: Hidden Culprits or Passive Participants? 355 (Level 3)			PANEL DISCUSSION Interorgan and Intercellular Cross Talk in Steatotic Liver R07 (Level 2)	



2026 SCIENTIFIC SESSIONS

Your registration includes on-demand access to content through August 10 to watch and rewatch sessions at your convenience.

To access on-demand content you will use your registration credentials at ADA2026.org.

#ADASciSessions